Clinical Trial Search

Primary: Skin Carotenoid Levels in Subjects With History of Squamous Cell Carcinoma Versus Control Subjects — 27,635; 31,219 Raman spectroscopy intensity counts — p=0.31

Primary: Cure Rate — 751 lesions

Primary: Mean Number of Squamous Cell Carcinomas — 0.75; 1.00 # of squamous cell carcinomas — p=0.750

Primary: This is a Study to Measure the Efficacy of the Nd:YAG Laser to Cause Complete Regression of Basal Cell Carcinoma. — 28 tumors

Primary: Difference in Basal Layer Keratinocytes Positive for Both Ki67 and Thymine Dimers — 21.5; 14.7 positive cells/1000 basal layer cells

Primary: Number of Participants With Complete Response — 9; 5; 7; 9 Participants

Primary: Number of Participants With Adverse Events — 10; 4; 1; 20 Participants

Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120

Primary: Change in Occurence of Local Skin Reaction (LSR) Side Effects TOTAL COMPOSITE SCORE — 7; 9; 4; 2 score on a scale

Primary: Number of Lesions With BCC Histological Clearance — 34 BCC Lesions

Primary: Number of Participants With Objective Response (Partial Response, Stable Disease and Progressive Disease) — 14; 4; 19 participants

Primary: Number of Participants With Sustained Clearance Rate of Superficial Basal Cell Carcinoma (sBCC) — 119 participants

Primary: Incidence of SCC — 3.1; 0.4 percentage of subjects

Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT Cycle — 80 percentage of participants

Primary: Change in Clinician Knowledge in Melanoma Risk and Lesion Identification — 72.1; 80.8 score on a scale — p=0.05

Primary: Percent Change in Biomarker (GLI2 Protein) Levels — 75 percentage decrease

Primary: Part 1: Percentage of Subjects With Discontinuations Due to Adverse Events — 0 Participants

Primary: Number of Control and Intervention Participants on Skin Self-examination Performance at Follow-up 1 Month After Intervention — 34; 8 Participants

Primary: The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed — 3.37; 3.52 years — p=0.93

Primary: Ki67 Tumor Proliferation Biomarker — 18; 0; -19; 13 Mean percent change — p=0.04

Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events

Primary: Overall Response Rate — 3 Participants

Primary: Complete Response Rate — 2 Participants

Primary: Overall Response Rate — 11; 1; 10 Participants — p=0.0005

Primary: Objective Response Rate (ORR) — 4; 1; 1 Participants

Primary: Number of New Onset Skin Cancer in Adult People Diagnosed With Vitiligo — 133; 812 Participants

Primary: Response Rate of Pembrolizumab — 72.73 percentage of participants

Primary: Reach of Personalized Genomic Testing for Melanoma. — 0; 204; 0; 295 Participants

Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants

Primary: Influence of a Patient's Melanoma Diagnosis on the Survivor's and Broader Family's Skin Cancer Prevention Activity. — 24; 22; 2; 5 Participants